Boston Scientific Initiates $2 Billion Accelerated Share Repurchase Program

summarizeSummary

Boston Scientific has commenced a $2 billion Accelerated Share Repurchase (ASR) program, utilizing a portion of its existing $5 billion authorization, with final settlement expected by June 30, 2026.

check_boxKey Events

• $2 Billion Accelerated Share Repurchase (ASR)

  Boston Scientific has entered into an ASR agreement for $2 billion of its common stock, part of its previously announced $5 billion share repurchase authorization.

• Significant Share Count Reduction

  The ASR is expected to repurchase approximately 30.4 million shares based on the May 15, 2026 closing price of $52.68, with the final number determined by the volume-weighted average price during the term.

• EPS Accretion Expected

  The ASR is projected to be $0.02 accretive to adjusted earnings per share for full year 2026, improving upon previously issued guidance.

• Remaining Buyback Authorization

  Following the completion of this ASR, Boston Scientific will have $3 billion remaining under its current share repurchase authorization.

auto_awesomeAnalysis

Boston Scientific is executing a significant portion of its previously authorized share repurchase program by launching a $2 billion Accelerated Share Repurchase (ASR). This move, representing a substantial capital allocation, is particularly notable as the company's stock is trading near its 52-week low. The ASR is expected to be accretive to adjusted EPS, signaling management's confidence in the company's valuation and commitment to returning value to shareholders.